

**FORM 5**

**UNITED STATES SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

OMB APPROVAL	
OMB Number:	3235-0362
Estimated average burden hours per response:	1.0

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Form 3 Holdings Reported.

Form 4 Transactions Reported.

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10

**ANNUAL STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* <u>Altamont Pharmaceutical Holdings, LLC</u>  (Last) (First) (Middle) 5960 BERKSHIRE LN FLOOR 6  (Street) DALLAS TX 75225  (City) (State) (Zip)	2. Issuer Name and Ticker or Trading Symbol <u>Galera Therapeutics, Inc. [ GRTX ]</u>	5. Relationship of Reporting Person(s) to Issuer (Check all applicable)  Director <input checked="" type="checkbox"/> 10% Owner  Officer (give title below) Other (specify below)
	3. Statement for Issuer's Fiscal Year Ended (Month/Day/Year) 12/31/2023	
	4. If Amendment, Date of Original Filed (Month/Day/Year)	6. Individual or Joint/Group Filing (Check Applicable Line)  <input checked="" type="checkbox"/> Form filed by One Reporting Person <input type="checkbox"/> Form filed by More than One Reporting Person

**Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned**

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)	4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned at end of Issuer's Fiscal Year (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
				Amount	(A) or (D)	Price			
Common Stock	01/11/2024	01/11/2024	S4	400,000	D	\$0.2256	4,880,000	I	See fn. <sup>(1)</sup>
Common Stock	03/22/2024	03/22/2024	S4	20,000	D	\$0.23	4,860,000	I	See fn. <sup>(1)</sup>
Common Stock	03/25/2024	03/25/2024	S4	780,000	D	\$0.2189	4,080,000	I	See fn. <sup>(1)</sup>
Common Stock	03/26/2024	03/26/2024	S4	2,000,000	D	\$0.1965	2,080,000	I	See fn. <sup>(1)</sup>
Common Stock	03/27/2024	03/27/2024	S4	306,924	D	\$0.1699	1,773,076	I	See fn. <sup>(1)</sup>
Common Stock	03/28/2024	03/28/2024	S	693,076	D	\$0.1459	1,080,000	I	See fn. <sup>(1)</sup>

**Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)**

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)	5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)	8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
					(A)	(D)	Date Exercisable	Expiration Date					

1. Name and Address of Reporting Person\*  
Altamont Pharmaceutical Holdings, LLC  
  
 (Last) (First) (Middle)  
 5960 BERKSHIRE LN  
 FLOOR 6  
  
 (Street)  
 DALLAS TX 75225  
  
 (City) (State) (Zip)

1. Name and Address of Reporting Person\*  
Pearson Mark E.  
  
 (Last) (First) (Middle)

5960 BERKSHIRE LN  
FLOOR 6

(Street)

DALLAS

TX

75225

(City)

(State)

(Zip)

**Explanation of Responses:**

1. Mark Pearson is the Manager and sole Member of Altamont Pharmaceutical Holdings LLC ("Altamont"). Altamont owns 5,280,000 shares of Galera Therapeutics, Inc. Mark Pearson does not personally own any shares. As the Manager and sole Member of Altamont, Mark Pearson possesses the power to vote and dispose of or direct the disposition of 5,280,000 shares.

/s/ Mark Pearson, Manager of

Altamont Pharmaceutical  
Holdings, LLC

04/01/2024

/s/ Mark Pearson

04/01/2024

\*\* Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

\* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.**